Abstract
First- and second-line strategies in chronic phase CML including hematopoietic stem cell transplantation
Highlights
The review article is dedicated to the main principles of modern therapy in chronic myeloid leukemia (CML)
According to the German CML Study Group the 10-year survival in CML has continuously improved,up to 85% with imatinib introduction
Switching to second-line TKI treatment and/or allogeneic Hematopoietic stem cell transplantation (HSCT) is recommended in cases of intolerance or drug resistance
Summary
Current treatment options for the chronic phase (CP) CML include Imatinib at standard or high doses (400 to 800 mg/d) and second-generation tyrosine kinase inhibitors (2-G TKIs), e. According to CML- Study IV the molecular responses (MR) achieved with imatinib in MR2 situations (an analogue of complete cytogenetic remission) may reach 92% after 10 years of observations. Switching to second-line TKI treatment and/or allogeneic HSCT is recommended in cases of intolerance or drug resistance.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
